Table 2.
Multivariable Cox regression models examining the independent associations of lymphopenia
| HR (95% CI), P-value |
|||||
|---|---|---|---|---|---|
| Model 1 | Model 2 | Model 3 | Model 4 | Model 5 | |
| Serology positive | 2.00 (1.67, 2.39), P < 0.001 | ||||
| ESR ≥ 25 | 1.65 (1.43, 1.90), P < 0.001 |
1.52 (1.32, 1.76), P < 0.001 |
1.52 (1.32, 1.76), P < 0.001 |
1.56 (1.35, 1.81), P < 0.001 |
1.61 (1.40, 1.87), P < 0.001 |
| PNL use | 2.53 (1.90, 3.37), P < 0.001 | 2.46 (1.83, 3.31), P < 0.001 | 2.47 (1.84, 3.32), P < 0.001 | 2.54 (1.89, 3.40), P < 0.001 | |
| IS or biologic use | 2.13 (1.78, 2.56), P < 0.001 |
2.06 (1.71, 2.48), P < 0.001 |
2.07 (1.72, 2.49), P < 0.001 |
2.13 (1.77, 2.56), P < 0.001 |
2.23 (1.86, 2.68), P < 0.001 |
| SLEDAI-2K score | 1.04 (1.02, 1.06), P < 0.001 | ||||
| SLEDAI-2K modifieda | 1.04 (1.02, 1.05), P < 0.001 | ||||
| SLEDAI-2K ≥ 6 | 1.18 (1.03, 1.37), P < 0.021 | ||||
| In LLDAS |
0.57 (0.50, 0.66), P < 0.001 |
||||
a
SLEDAI-2K modified excludes leucopenia. HR: hazard ratio; IS: immunosuppressant; LLDAS: lupus low disease activity state; PNL: prednisolone.